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Experimental procedure
All the chemicals and solvents used were purchased from various chemical suppliers and were used without further purification. Melting points were determined using a Reichert hot stage microscope and are uncorrected. The progress of the reactions was monitored by thin layer chromatography (TLC) using Merck F254 silica gel plates supported on aluminium. The desired intermediates were purified by a silica gel column chromatography using Merck Kieselgel 60 Å: A mixture of aqueous solution of monobasic sodium phosphate 0.01M and acetonitrile (90:10) on isocratic elution mode was used as the mobile phase. Five different concentrations (5 -500 µg/mL) of samples to be analysed were made, filtered using 0.45 µm Millipore filters before their injection.
General synthesis for aroylhydrazone conjugates
A 100 mL round bottom flask was charged with 20 mL of 95 % ethanol, 400-500 mg of 4 or 5, few drops of glacial acetic acid and 1.5 equivalent of isoniazid. The mixture was stirred under reflux for 12-24 h. The products precipitated out during the course of reaction, and were filtered, washed twice with 10 mL portions of ethanol and dried to obtain 200-400 mg of target compounds in 30-70 % yields. 1, 176.2, 164.1, 150.2, 142.2, 135.7, 133.4, 132.2, 132.0, 129.3, 127.4, 121.6, 118.9, 112.7, 111.9, 72.7, 69.7, 60.7, 55.02, 39.7, 27. 
Ethyl (E)-1-ethyl-6-(1-(2-isonicotinoylhydrazono)ethyl)-4-oxo-1,4-dihydroquinoline-3carboxylate, 11
Orange powder, 350 mg ( 5, 172.6, 164.9, 155.9, 150.6, 150.0, 140.0, 134.4, 131.0, 128.4, 125.1, 126.4, 122.3, 117.9, 111.1, 60.2, 49.0, 15.1, 14.8, 14.7 175.7, 164.3, 155.9, 150.6, 148.6, 140.3, 134.9, 131.2, 127.5, 124.8, 122.5, 122.2, 118.2, 111.8, 72.7, 58.6, 48.9, 38.2, 15.2, 14.9 4, 175.7, 165.3, 154.5, 148.8, 148.0, 147.9, 146.8, 139.1, 134.5, 133.2, 132.3, 130.6, 123.8, 122.3, 121.6, 119.7, 110.1, 49.6, 47.2, 35.9, 29.2, 14.0, 13.8 4, 129.0, 128.4, 127.5, 127.0, 125.1, 123.8, 122.4, 118.7, 111.8, 57.9, 56.8, 49.6, 47.1, 35.9, 15 1-(4-bromobenzyl)-N-(2-((2-hydroxyethyl) 7, 172.6, 164.3, 150.5, 150.0, 149.2, 141.5, 140.0, 135.8, 134.6, 132.2, 129.1, 127.3, 124.5, 123.6, 122.8, 121.4, 118.3, 112.2, S8 72.6, 69.8, 60.7, 55.9, 39.3, 20. N-(2-((2-hydroxyethyl) 4, 165.3, 164.3, 155.9, 153.8, 150.5, 145.6, 140.7, 136.4, 132.1, 130.2, 128.1, 127.7, 127.5, 127.3, 126.3, 126.1, 125.5, 123.8, 120.9, 116.0, 112.0, 57.0, 51.0, 49.6, 47.1, 35.8, 15.4 . ESI-HRMS m/z calcd for 3, 166.0, 164.3, 155.6, 151.6, 146.9, 138.6, 135.3, 133.9, 131.9, 131.5, 130.8, 129.4, 128.8, 127.5, 126.1, 124.8, 122.0, 118.8, 115.0, 111.7, 71.2, 59.3, 58.5, 38.8, 15. 
In vitro cytotoxicity assay
HeLa cells seeded in 96-well plates were incubated with 20 µM test compounds for 24 hours and cell viability assessed using a resazurin fluorescence assay as previously described. 41
In vitro antimycobacterial assay
The minimum inhibitory concentration (MIC) was determined using the standard broth micro dilution method, where a 10 mL culture of Mycobacterium tuberculosis pMSp12::GFP, 42 was grown to an absorbance (OD600) of 0.6 -0.7. The medium used was Middlebrook 7H9 supplemented with 0.03% casitone, 0.4% glucose, and 0.05% tyloxapol. 43 Cultures grown in this medium are diluted 1:500, prior to inoculation of the MIC assay. The compounds to be tested were reconstituted to a concentration of 10 mM in DMSO. Two-fold serial dilutions of the test compound were prepared across a 96-well micro titre plate, after which, 50 μL of the diluted M.
tuberculosis cultures was added to each well in the serial dilution. The plate layout was a modification of the method previously described. 44 Assay controls used were a minimum growth control (Rifampicin at 2 × MIC), and a maximum growth control (5% DMSO). The micro titre plates were sealed in a secondary container and incubated at 37 °C with 5% CO 2 and humidification. Relative fluorescence (excitation 485 nM; emission 520 nM) was measured using a plate reader (FLUOstar OPTIMA, BMG LABTECH), at day 7 and day 14. The raw fluorescence data were archived and analysed using the CDD Vault from Collaborative Drug Discovery, in which, data were normalised to the minimum and maximum inhibition controls to generate a dose response curve (% inhibition), using the Levenberg-Marquardt damped least squares method, from which the MIC 90 was calculated (Burlingame, CA www.collaborativedrug.com). The lowest concentration of drug that inhibited growth of more than 90 % of the mycobacterial population was considered to be the MIC 90 .
Kinetic solubility determination using nephelometry
The solubility assay was performed (H3-D, University of Cape Town) using a miniaturised shake flask method. 45 10 mM stock solutions of each of the test compounds were used to prepare calibration standards (10-220 μM) in DMSO, and to spike (1:50) duplicate aqueous samples of phosphate buffered saline (pH 6.5). The DMSO was dried off using a GeneVac (MiVac, 90 min, 37 C). After shaking (20 hours, 25 C), the solutions were filtered and analysed by means of HPLC-DAD (Agilent 1200 Rapid Resolution HPLC with a diode array detector). Best fit S10 calibration curves were constructed using the calibration standards, which were used to determine the aqueous samples' solubility.
In vitro metabolic stability using human, rat and mouse liver microsomes
All protocols for in vitro metabolic studies were done in collaboration with Drug Discovery and 
